Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05937594 · ClinicalTrials.gov registry record
MicroRNA Biomarkers for Neonatal Opioid Withdrawal Syndrome
A clinical trial of Neonatal Abstinence Syndrome and Neonatal Opioid Withdrawal Syndrome, sponsored by Milton S. Hershey Medical Center.
- Recruiting
- Registry status
- 50
- Enrollment target
- 1
- Study location
NCT05937594 is a study of Neonatal Abstinence Syndrome and Neonatal Opioid Withdrawal Syndrome that is actively recruiting participants, run by Milton S. Hershey Medical Center. The registered enrollment target is 50 participants, below the 64-participant average among 17 other Neonatal Abstinence Syndrome trials with a reported enrollment target (22% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05937594, a study of Neonatal Abstinence Syndrome and Neonatal Opioid Withdrawal Syndrome, is actively recruiting participants, sponsored by Milton S. Hershey Medical Center.
- RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
Infants with neonatal abstinence syndrome (NAS) experience prolonged hospital stays and poor neurodevelopmental outcomes, in-part because of the lack of accurate, individualized, biologic assessments available to manage this increasingly common medical condition. The proposed study will define the molecular mechanisms that regulate the response to opioid withdrawal in the developing brain by focusing on three candidate microRNAs (let-7a, miR-146a, miR-192) that have been shown to respond to opioid exposure in animal models and adults, and are impacted in both my preliminary study of infants with NAS, and my human neural progenitor cell (NPC) design of opioid withdrawal. By determining the mechanism through which microRNAs impact NPC differentiation in opioid withdrawal, and determining whether exosomal salivary microRNA levels predict treatment dose and neurodevelopmental outcomes in infants with NAS, this study will enhance our knowledge of NAS-related biology and identify potential biomarkers that could improve medical care for this important medical condition.
Conditions Studied
Interventions
- GENETIC Buccal swab saliva for further genetic testing
Study Locations (1)
Pennsylvania
- Penn State Milton S. Hershey Medical Center - Hershey
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2020-01-15 |
| Est. Completion | 2027-04-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05937594
The ClinicalTrials.gov registry entry for NCT05937594 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 64-participant average among 17 other Neonatal Abstinence Syndrome trials with a reported enrollment target (22% lower). The listed sponsor is Milton S. Hershey Medical Center, which has 396 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Neonatal Abstinence Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Buccal swab saliva for further genetic testing is the first listed.
NCT05937594 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05937594 about?
NCT05937594 is a clinical study titled "MicroRNA Biomarkers for Neonatal Opioid Withdrawal Syndrome". Infants with neonatal abstinence syndrome (NAS) experience prolonged hospital stays and poor neurodevelopmental outcomes, in-part because of the lack of accurate, individualized, biologic assessments available to manage this increasingly common medical condition. The proposed study will define the m...
What is the current status of trial NCT05937594?
This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2020-01-15. Estimated completion is 2027-04-10.
What conditions does trial NCT05937594 study?
This clinical trial studies the following conditions: Neonatal Abstinence Syndrome, Neonatal Opioid Withdrawal Syndrome.
What interventions are being tested in trial NCT05937594?
The interventions under investigation include: Buccal swab saliva for further genetic testing (GENETIC).
Who is sponsoring clinical trial NCT05937594?
This trial is sponsored by Milton S. Hershey Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05937594 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neonatal Abstinence Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Intervention Mapping Approach to Closing the Gap in Maternal OUD and Infant NAS Care (SUPPORT)
RECRUITING · NA
-
A Trial to Determine Weight Gain Benefits of Caloric Supplementation for NAS Infants
ACTIVE NOT RECRUITING · NA
-
Effective Caregiving for Neonatal Abstinence Syndrome: Testing an Instructional Mobile Technology Platform for High-Risk Pregnant Women
ACTIVE NOT RECRUITING · NA
-
Treatment of Neonatal Abstinence Syndrome With Clonidine Versus Morphine as Primary Therapy
ACTIVE NOT RECRUITING · Phase 4
-
Neurostimulation to Improve NOWS Outcomes
ACTIVE NOT RECRUITING · NA
-
Buprenorphine for Treatment of Neonatal Abstinence Syndrome in Infants With In Utero Exposure to Benzodiazepines
COMPLETED · Phase 1
Explore more on PlainTrial
Neonatal Abstinence Syndrome
All registered trials for this condition
Neonatal Opioid Withdrawal Syndrome
All registered trials for this condition
Pennsylvania
All trials with a study site in Pennsylvania
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.